Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants.

Fraile-Ribot P, Zamorano L, Orellana R, Barrio-Tofiño ED, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas study Group.

Antimicrob Agents Chemother. 2019 Nov 18. pii: AAC.02165-19. doi: 10.1128/AAC.02165-19. [Epub ahead of print]

PMID:
31740559
2.

A standard numbering scheme for class C β-lactamases.

Mack AR, Barnes MD, Taracila MA, Hujer AM, Hujer KM, Cabot G, Feldgarden M, Haft DH, Klimke W, van den Akker F, Vila AJ, Smania A, Haider S, Papp-Wallace KM, Bradford PA, Rossolini GM, Docquier JD, Frère JM, Galleni M, Hanson ND, Oliver A, Plésiat P, Poirel L, Nordmann P, Palzkill TG, Jacoby GA, Bush K, Bonomo RA.

Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01841-19. doi: 10.1128/AAC.01841-19. [Epub ahead of print]

PMID:
31712217
3.

Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections.

Torrens G, Escobar-Salom M, Pol-Pol E, Camps-Munar C, Cabot G, López-Causapé C, Rojo-Molinero E, Oliver A, Juan C.

Front Microbiol. 2019 Aug 27;10:1868. doi: 10.3389/fmicb.2019.01868. eCollection 2019.

4.

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey.

Del Barrio-Tofiño E, Sánchez-Diener I, Zamorano L, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI .

J Antimicrob Chemother. 2019 Nov 1;74(11):3217-3220. doi: 10.1093/jac/dkz346.

PMID:
31430372
5.

Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.

Arca-Suárez J, Fraile-Ribot P, Vázquez-Ucha JC, Cabot G, Martínez-Guitián M, Lence E, González-Bello C, Beceiro A, Rodríguez-Iglesias M, Galán-Sánchez F, Bou G, Oliver A.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e01110-19. doi: 10.1128/AAC.01110-19. Print 2019 Oct.

PMID:
31383659
6.

Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections.

Sánchez-Diener I, Zamorano L, Peña C, Ocampo-Sosa A, Cabot G, Gómez-Zorrilla S, Almirante B, Aguilar M, Granados A, Calbo E, Rodriguez-Baño J, Rodríguez-López F, Tubau F, Martínez-Martínez L, Navas A, Oliver A.

Clin Microbiol Infect. 2019 Jul 6. pii: S1198-743X(19)30389-1. doi: 10.1016/j.cmi.2019.06.034. [Epub ahead of print]

PMID:
31288102
7.

Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology.

Del Barrio-Tofiño E, Zamorano L, Cortes-Lara S, López-Causapé C, Sánchez-Diener I, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas study Group .

J Antimicrob Chemother. 2019 Jul 1;74(7):1825-1835. doi: 10.1093/jac/dkz147.

PMID:
30989186
8.

Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins.

Torrens G, Barceló IM, Pérez-Gallego M, Escobar-Salom M, Tur-Gracia S, Munar-Bestard M, González-Nicolau MDM, Cabrera-Venegas YJ, Rigo-Rumbos EN, Cabot G, López-Causapé C, Rojo-Molinero E, Oliver A, Juan C.

Sci Rep. 2019 Mar 5;9(1):3575. doi: 10.1038/s41598-019-40440-w.

9.

In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.

Moya B, Barcelo IM, Cabot G, Torrens G, Palwe S, Joshi P, Umarkar K, Takalkar S, Periasamy H, Bhagwat S, Patel M, Bou G, Oliver A.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00128-19. doi: 10.1128/AAC.00128-19. Print 2019 May.

10.

Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa.

Cabot G, Florit-Mendoza L, Sánchez-Diener I, Zamorano L, Oliver A.

J Antimicrob Chemother. 2018 Dec 1;73(12):3322-3331. doi: 10.1093/jac/dky364.

PMID:
30189050
11.

The Versatile Mutational Resistome of Pseudomonas aeruginosa.

López-Causapé C, Cabot G, Del Barrio-Tofiño E, Oliver A.

Front Microbiol. 2018 Apr 6;9:685. doi: 10.3389/fmicb.2018.00685. eCollection 2018. Review.

12.

Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting.

López-Causapé C, Rubio R, Cabot G, Oliver A.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02583-17. doi: 10.1128/AAC.02583-17. Print 2018 Apr.

13.

Erratum for del Barrio-Tofiño et al., "Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain".

Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02352-17. doi: 10.1128/AAC.02352-17. Print 2018 Jan. No abstract available.

14.

Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.

Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Martín-Pena ML, Juan C, Pérez JL, Oliver A.

J Antimicrob Chemother. 2018 Mar 1;73(3):658-663. doi: 10.1093/jac/dkx424.

PMID:
29149337
15.

Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model.

Sánchez-Diener I, Zamorano L, López-Causapé C, Cabot G, Mulet X, Peña C, Del Campo R, Cantón R, Doménech-Sánchez A, Martínez-Martínez L, Arcos SC, Navas A, Oliver A.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01586-17. doi: 10.1128/AAC.01586-17. Print 2017 Dec.

16.

Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.

Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01589-17. doi: 10.1128/AAC.01589-17. Print 2017 Nov. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

17.

Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system.

Torrens G, Pérez-Gallego M, Moya B, Munar-Bestard M, Zamorano L, Cabot G, Blázquez J, Ayala JA, Oliver A, Juan C.

PLoS One. 2017 Jul 25;12(7):e0181932. doi: 10.1371/journal.pone.0181932. eCollection 2017.

18.

Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone.

López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, Figuerola J, Cantón R, Kidd TJ, Molin S, Oliver A.

Sci Rep. 2017 Jul 17;7(1):5555. doi: 10.1038/s41598-017-05621-5.

19.

In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.

Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Pérez JL, Oliver A.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01117-17. doi: 10.1128/AAC.01117-17. Print 2017 Sep.

20.

Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model.

Gómez-Zorrilla S, Calatayud L, Juan C, Cabot G, Tubau F, Oliver A, Dominguez MA, Ariza J, Peña C.

Int J Antimicrob Agents. 2017 Feb;49(2):198-203. doi: 10.1016/j.ijantimicag.2016.10.016. Epub 2016 Nov 28.

PMID:
27939091
21.

Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?

Pérez-Gallego M, Torrens G, Castillo-Vera J, Moya B, Zamorano L, Cabot G, Hultenby K, Albertí S, Mellroth P, Henriques-Normark B, Normark S, Oliver A, Juan C.

MBio. 2016 Oct 25;7(5). pii: e01783-16. doi: 10.1128/mBio.01783-16.

22.

Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MÁ, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Plesiat P, Oliver A.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7415-7423. Print 2016 Dec.

23.

Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.

Torrens G, Cabot G, Ocampo-Sosa AA, Conejo MC, Zamorano L, Navarro F, Pascual Á, Martínez-Martínez L, Oliver A.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6407-10. doi: 10.1128/AAC.01282-16. Print 2016 Oct.

24.

Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies.

Gómez-Zorrilla S, Juan C, Cabot G, Camoez M, Tubau F, Oliver A, Dominguez MA, Ariza J, Peña C.

Int J Antimicrob Agents. 2016 May;47(5):368-74. doi: 10.1016/j.ijantimicag.2016.02.010. Epub 2016 Mar 24.

PMID:
27079153
25.

Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.

Rojo-Molinero E, Macià MD, Rubio R, Moyà B, Cabot G, López-Causapé C, Pérez JL, Cantón R, Oliver A.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2912-22. doi: 10.1128/AAC.00196-16. Print 2016 May.

26.

Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.

Cabot G, Zamorano L, Moyà B, Juan C, Navas A, Blázquez J, Oliver A.

Antimicrob Agents Chemother. 2016 Jan 4;60(3):1767-78. doi: 10.1128/AAC.02676-15.

27.

Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure.

Ropy A, Cabot G, Sánchez-Diener I, Aguilera C, Moya B, Ayala JA, Oliver A.

Antimicrob Agents Chemother. 2015 Jul;59(7):3925-34. doi: 10.1128/AAC.05150-14. Epub 2015 Apr 20.

28.

N-acetylcysteine selectively antagonizes the activity of imipenem in Pseudomonas aeruginosa by an OprD-mediated mechanism.

Rodríguez-Beltrán J, Cabot G, Valencia EY, Costas C, Bou G, Oliver A, Blázquez J.

Antimicrob Agents Chemother. 2015;59(6):3246-51. doi: 10.1128/AAC.00017-15. Epub 2015 Mar 23.

29.

Draft Genome Sequence of the Quorum-Sensing and Biofilm-Producing Pseudomonas aeruginosa Strain Pae221, Belonging to the Epidemic High-Risk Clone Sequence Type 274.

Ocampo-Sosa AA, Fernández-Martínez M, Cabot G, Peña C, Tubau F, Oliver A, Martínez-Martínez L.

Genome Announc. 2015 Jan 15;3(1). pii: e01343-14. doi: 10.1128/genomeA.01343-14.

30.

Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.

Peña C, Cabot G, Gómez-Zorrilla S, Zamorano L, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V, Aguilar M, Granados A, Calbo E, Rodríguez-Baño J, Rodríguez-López F, Tubau F, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Clin Infect Dis. 2015 Feb 15;60(4):539-48. doi: 10.1093/cid/ciu866. Epub 2014 Nov 6.

PMID:
25378459
31.

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.

Antimicrob Agents Chemother. 2014 Jun;58(6):3091-9. doi: 10.1128/AAC.02462-13. Epub 2014 Mar 17.

32.

Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.

Mulet X, Cabot G, Ocampo-Sosa AA, Domínguez MA, Zamorano L, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2013 Nov;57(11):5527-35. doi: 10.1128/AAC.01481-13. Epub 2013 Aug 26.

33.

Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection.

López-Causapé C, Rojo-Molinero E, Mulet X, Cabot G, Moyà B, Figuerola J, Togores B, Pérez JL, Oliver A.

PLoS One. 2013 Aug 12;8(8):e71001. doi: 10.1371/journal.pone.0071001. eCollection 2013.

34.

A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria.

Torres-Barceló C, Cabot G, Oliver A, Buckling A, Maclean RC.

Proc Biol Sci. 2013 Feb 27;280(1757):20130007. doi: 10.1098/rspb.2013.0007. Print 2013 Apr 22.

35.

Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones.

Cabot G, Ocampo-Sosa AA, Domínguez MA, Gago JF, Juan C, Tubau F, Rodríguez C, Moyà B, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2012 Dec;56(12):6349-57. doi: 10.1128/AAC.01388-12. Epub 2012 Oct 8.

36.

Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A.

Antimicrob Agents Chemother. 2012 Sep;56(9):4771-8. doi: 10.1128/AAC.00680-12. Epub 2012 Jun 25.

37.

Alterations of OprD in carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from patients with bacteremia in a Spanish multicenter study.

Ocampo-Sosa AA, Cabot G, Rodríguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L, Suárez C, Peña C, Domínguez MA, Moncalián G, Oliver A, Martínez-Martínez L; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2012 Apr;56(4):1703-13. doi: 10.1128/AAC.05451-11. Epub 2012 Jan 30.

38.

Environmental microbiota represents a natural reservoir for dissemination of clinically relevant metallo-beta-lactamases.

Scotta C, Juan C, Cabot G, Oliver A, Lalucat J, Bennasar A, Albertí S.

Antimicrob Agents Chemother. 2011 Nov;55(11):5376-9. doi: 10.1128/AAC.00716-11. Epub 2011 Aug 22.

39.

Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals.

García-Castillo M, Del Campo R, Morosini MI, Riera E, Cabot G, Willems R, van Mansfeld R, Oliver A, Cantón R.

J Clin Microbiol. 2011 Aug;49(8):2905-10. doi: 10.1128/JCM.00753-11. Epub 2011 Jun 22.

40.

Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.

Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.

J Antimicrob Chemother. 2011 Sep;66(9):2022-7. doi: 10.1093/jac/dkr232. Epub 2011 Jun 8.

PMID:
21653605
41.

[Assessment of glycemic control: new insights into the evaluation of the diabetic patient].

González Clemente JM, Cabot GL.

Med Clin (Barc). 2010 Sep;135 Suppl 2:15-9. doi: 10.1016/S0025-7753(10)70028-2. Spanish.

PMID:
21420533
42.

AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.

Zamorano L, Reeve TM, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.

Antimicrob Agents Chemother. 2011 May;55(5):1990-6. doi: 10.1128/AAC.01688-10. Epub 2011 Feb 28.

43.

Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.

Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A; Spanish Network for Research in Infectious Diseases (REIPI).

Antimicrob Agents Chemother. 2011 May;55(5):1906-11. doi: 10.1128/AAC.01645-10. Epub 2011 Feb 28.

44.

NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.

Zamorano L, Reeve TM, Deng L, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.

Antimicrob Agents Chemother. 2010 Sep;54(9):3557-63. doi: 10.1128/AAC.00385-10. Epub 2010 Jun 21.

45.

[Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy].

Bros JA, Lluís PG, Cabot GL, Pedragós AC.

Med Clin (Barc). 2011 Feb 26;136(5):207-14. doi: 10.1016/j.medcli.2009.05.022. Epub 2009 Jul 30. Review. Spanish. No abstract available.

PMID:
19646718
46.

Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization.

Tosi S, Cabot G, Giudici G, Attuati V, Morandi P, Rambaldi A, Döhner H, Biondi A.

Cancer Genet Cytogenet. 1996 Jul 15;89(2):153-6.

PMID:
8697423
47.

High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears.

Cabot GP, Bentz M, Scholl C, Moos M, Fischer K, Lichter P, Döhner H.

Cancer Genet Cytogenet. 1996 Apr;87(2):107-11.

PMID:
8625254
48.

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, et al.

Blood. 1995 Mar 15;85(6):1580-9.

PMID:
7888675
49.

Molecular cytogenetic analysis of RB-1 deletions in chronic B-cell leukemias.

Döhner H, Pilz T, Fischer K, Cabot G, Diehl D, Fink T, Stilgenbauer S, Bentz M, Lichter P.

Leuk Lymphoma. 1994 Dec;16(1-2):97-103.

PMID:
7696936
50.

Fluorescence in situ hybridization in leukemias: 'the FISH are spawning!'.

Bentz M, Döhner H, Cabot G, Lichter P.

Leukemia. 1994 Sep;8(9):1447-52. Review.

PMID:
8090024

Supplemental Content

Support Center